Fundz

Akamis Bio Strengthens Leadership Team with Key Executive Appointments | BioSpace

PRIVATEJul 06, 2023

Position

Chief Medical Officer

Company

Akamis Bio

Oliver Rosen
oliver.rosen@akamisbio.com
BiotechnologyHealth CareGeneticsTherapeutics

Description

Company Names Dr. Oliver Rosen Chief Medical Officer and Peter Kosa Chief Business Officer; Samantha Bailey-Bucktrout Promoted to Senior Vice President, Head of Research","CAMBRIDGE, Mass. & OXFORD, England---- Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy platform to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors, today announced the appointment of Oliver Rosen, M.D

Quick answer

Akamis Bio Strengthens Leadership Team with Key Executive Appointments | BioSpace (July 6, 2023).

What did Akamis Bio announce on July 6, 2023?
Company Names Dr. Oliver Rosen Chief Medical Officer and Peter Kosa Chief Business Officer; Samantha Bailey-Bucktrout Promoted to Senior Vice President, Head of Research","CAMBRIDGE, Mass. & OXFORD, England---- Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy platform to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat...
What does Akamis Bio do?
Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer.
Which similar companies made leadership changes around the same time?
Elevation Oncology (July 13, 2023), HuidaGene Therapeutics (May 24, 2023), Biosion (July 5, 2023) and EyePoint, Inc. (July 10, 2023) also announced leadership changes within 45 days of Akamis Bio.

Source: Fundz verified event record.

Other recent leadership changes in Genetics and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Akamis Bio, and when

A new leader at Akamis Bio brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Akamis Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Akamis Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Akamis Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Akamis Bio

Location

Abingdon Science Park Barton Lane

About

Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer. To achieve that mission, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. Akamis Bio has a growing pipeline of T-SIGn® therapeutics anchored by its two clinical-stage programs, NG-350A (an immuno-stimulatory tumor gene therapy driving intratumoral expression of a CD40 agonist monoclonal antibody) and NG-641 (a stromal-targeted tumor gene therapy leveraging a viral vector encoding a FAP-CD3 bispecific antibody, CXCL-9, CXCL-10 & interferon alpha). NG-350A and NG-641 are both being investigated in ongoing Phase 1 clinical studies in patients with metastatic or advanced epithelial tumors. In addition to internal pipeline development efforts, Akamis Bio has a number of T-SIGn® platform-focused collaborations with leaders in the immuno-oncology field including BMS, Merck, and the Parker Institute for Cancer Immunotherapy (PICI).

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Akamis Bio changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Oliver
Likely contact at this company
••••••••@••••••••

See Oliver's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Akamis Bio's next move

Learn about Strategic plan

Akamis Bio changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.